Clinical trial

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

NCT02811497

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-09-01

PhasePHASE2

Study timeline

Study start (unknown)2016-09-01Date precision: month

Registry last updated2021-04-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Microsatellite Stable Colorectal Carcinomaunresolved

Platinum Resistant Epithelial Ovarian Cancer Type IIunresolved

Estrogen Receptor Positive and HER2 Negative Breast Cancerunresolved

Interventions

AzacitidineDRUG · verified · RxNorm: azacitidine

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

University Health Network, Torontolead sponsor

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02811497 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.